ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. - Csizmar CM; Gurney M; Kanagal-Shamanna R; Chien K; Hammond D; Lasho TL; Finke CM; Dean C; Natu A; Mangaonkar AA; Al-Kali A; Gangat N; et al. (Haematologica, 2024)